CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in two upcoming investor conferences. Details regarding Lifecore’s participation are as follows:
Details: Paul Josephs, Lifecore’s president and chief executive officer, will deliver a corporate presentation and Lifecore management will participate in investor meetings
Conference Dates: November 17-20, 2025
Presentation Time/Date: 9:30 – 9:55 a.m. Greenwich Mean Time (4:30 – 4:55 a.m. Eastern Time) on Tuesday, November 18, 2025, webcast available
Location: London, UK
Details: Mr. Josephs will be a featured speaker in a fireside chat and Lifecore management will participate in 1-on-1 meetings
Conference Dates: November 18-20, 2025
Fireside Chat Time/Date: 9:00 – 9:45 a.m. Central Time on Thursday, November 20, 2025, webcast available
Location: Nashville
Webcasts of the Jefferies presentation and the Stephens fireside chat may be accessed via a link on Lifecore’s investor website on the Investor Events & Presentations page at: https://ir.lifecore.com/events-presentations. Additionally, replays of the webcasts will be available on the Lifecore website following the conference.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
| Last Trade: | US$7.90 |
| Daily Change: | 0.07 0.89 |
| Daily Volume: | 67,182 |
| Market Cap: | US$296.010M |
November 06, 2025 October 29, 2025 October 28, 2025 August 07, 2025 June 17, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
